We are live on ! Find out more
HAE icon

Haemonetics

297 hedge funds and large institutions have $4.37B invested in Haemonetics in 2024 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 102 increasing their positions, 114 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

190% more call options, than puts

Call options by funds: $14.6M | Put options by funds: $5.04M

22% more capital inflows, than outflows

Capital inflows: $378M | Capital outflows: $310M

1.09% more ownership

Funds ownership: 99.66% → 100.74% (+1.1%)

3% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 40

1% more funds holding

Funds holding: 295 → 297 (+2)

11% less repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 114

Holders
297
Holders Change
+2
Holders Change %
+0.68%
% of All Funds
4.26%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
41
Increased
102
Reduced
114
Closed
40
Calls
$14.6​M
Puts
$5.04​M
Net Calls
+$9.6​M
Net Calls Change
-⁠$1.66​M

HAE Hedge Fund Activity: Q1 2024 in Review

297 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2024, worth a combined $4.37B — up 0.97% from $4.32B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new HAE positions and 40 closed out — a net gain of 1 holder — while 102 added to existing stakes and 114 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $78.7M. The largest seller was Fidelity Investments, cutting an estimated $109M.

  • 297 institutional investors held Haemonetics (HAE) as of Q1 2024, up from 295 in Q4 2023.
  • Funds reported $4.37B of Haemonetics stock for Q1 2024, up 0.97% quarter-over-quarter.
  • 41 funds opened new Haemonetics positions in Q1 2024 and 40 closed out, a net change of +1 holder.
  • The largest Haemonetics buyer in Q1 2024 was Wellington Management Group, an estimated $78.7M added.
  • The largest Haemonetics seller in Q1 2024 was Fidelity Investments, an estimated $109M sold.

Based on aggregated 13F filings for Q1 2024.